User loginNavigation |
Washington Launched Me, But I am Proud to be a Lebanese Dreaming of New Technology - Al AnwarBy Nihad Tobalian Lebanese businessman Fuad El-Hibri is the “Entrepreneur of the Year for 2009” for the Washington, DC area, and earned this award from Ernst & Young’s Global Technology Group, which is given to honor businessmen who lead nascent companies to growth in their specialized area of work. He earned this award for leading his American company, “Emergent BioSolutions,” which he transformed from a stumbling company into a pioneer company in the field of development of medical vaccines. What are the details of this award, and the types of vaccines that the 51-year-old El-Hibri has developed? During a meeting with Anwar, businessman Fuad El-Hibri, who spends his annual vacation in Lebanon, said: From this award, “Ernst & Young” is seeking major companies that apply quality standards of work and production and the ability to develop new products, against the contribution of these companies in the development and preservation of the community. What helped us as “Emergent BioSolutions” to win this award, specifically for the category of technology in the Washington metropolitan area, is our adherence to the requirement of the award, especially after the recent acquisition of the company, which was for sale for approximately $25 million, and which has 170 employees. Through expansion and development strategy, the price of the company rose to between 400 and 500 million dollars, according to the New York Stock Exchange, as the price per share has risen from six dollars ten years ago to 26 dollars, in addition to increasing the number of employees to 600 employees, which helped us to increase the volume of our business, especially since our approved strategy was also based on a policy of expansion through the acquisition of three money losing companies in the United States, Britain and Germany.
“Ernst & Young,” explains businessman Fuad El-Hibri, “is a global financial company that exercises financial control over companies, and honors those who achieve their aspirations and consequently, their achievements in the creative and innovative areas in the field of technology. After that, a panel of judges selects a ‘Leading Businessman.’ Ernst &Young selected me as the pioneer businessman for 2009 in the field of technology, in my capacity as owner of the company ‘Emergent BioSolutions.’ And while I am proud of the award, I am also proud of every employee in the company, because they all, in addition to being loyal to the company, believe in what we do, and devote themselves to work, especially since the scope of our work requires protecting human life. It is true that the company has a business face, but the primary nature of our work is to protect human life through the development of vaccines that will provide them with immunity against disease. The motto with which we operate the commercial side does not negate the human aspect.” University ● You spoke about the specialized vaccines that the company you own develop. What are these vaccines? And against which diseases do they work?
● What about the work on a vaccine for cancer, for which effective medical treatments have not been found? - We are working on a number of vaccines for multiple diseases, including for example, work on the development of a vaccine to increase the effectiveness of an old vaccine. For example, there is an effective vaccine for typhoid, but we are working to develop a single dose vaccine, to be administered orally, not with a needle. As for internal diseases, such as internal inflammations for example, we have two technical working groups at the company studying the possibility of trying to find volunteers to receive these vaccines. However, I think it is premature to talk about this vaccine, because we are still in the early stages of the work, and specifically, we are still at the exploration stage. However, in this connection, if we were to look at this issue from a scientific point of view, vaccines are the most advanced in the pharmaceutical industry. Biological studies have shown that vaccines, and immunity enhancement and vaccination are more mature in biological research than they are in the pharmaceutical industry. ● Those who are familiar with your curriculum vitae will find that you specialize in economics. What led you to work in the medical treatment field?
Submitted by admin on Wed, 10/14/2009 - 12:10. categories [ ]
|
Category CloudTag CloudWho's new
Who's onlineThere are currently 0 users and 2 guests online.
Recent comments
|
70-541(CSHARP) practice
wholesale new era
Nike Ken Griffey shoes air
UGG boots are popular among
Some dealers and replica
well,the following i will do
Bone Black is a book ugg
Dresses, evening, cocktail,
Prom dresses wedding
MS Office 2007
adfa [url=http://www.adasd.co
align shark basis vr arabs
I think that this
I think that this organization is doing really good work, I'd buy thesis on it.
Hi! I have seen many such
This is great article of
This is great article of such a great Interpreneur, who made all this possible on his own. His business of vaccines has not only given him name and fame but also have given so much more help to the community and the country. Vaccines are so important in the medical field, saves many lifes. So, this is really a great thing to read about. Nice Blog.Plastic Injection Molding
Post new comment